XBiotech Inc.

XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

XBITNasdaqHealthcareBiotechnology
$2.43 +0.05 (+2.10%)

Company Overview

XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Price Chart

Historical Trend (Absolute Values)
XBIT Price
05/1505/2606/02

Financial Metrics

Market Capitalization$72.26M
P/E Ratio
Earnings Per Share (EPS)-$1
Dividend Yield
Beta (Volatility)0.863
Price to Book (P/B)0.5279
52-Week Range$2.09 - $3.61

LAST SCRARED: June 2, 2026

Compare XBIT

Analyze valuation multiples and growth parameters side-by-side with other public equities.

Compare Stock Now
VersusHub

© 2026 VersusHub. All rights reserved.